Qsemble Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Qsemble Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	31,633 -4,937	-14%	-$346K	0.3%	127
2026 Q1	$2.72M	Buy	+36,570	New	+$2.65M	0.21%	163
2025 Q4	–	Sell	-55,320	Closed	-$2.87M	–	489
2025 Q3	$2.87M	Buy	55,320 +12,975	+31%	+$633K	0.28%	115
2025 Q2	$1.83M	Sell	42,345 -253	-0.6%	-$9.2K	0.18%	176
2025 Q1	$1.47M	Buy	+42,598	New	+$1.44M	0.16%	186

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Qsemble Capital Management's BBIO Position: Q2 2026 in Review

Qsemble Capital Management reduced its BridgeBio Pharma (BBIO) stake by 14% in Q2 2026, selling an estimated $346K and leaving 31,633 shares worth $2.36M. The position accounts for 0.3% of the portfolio, ranked #127.

Qsemble Capital Management first reported a position in BBIO in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.87M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Qsemble Capital Management held 31,633 shares of BridgeBio Pharma worth $2.36M as of Q2 2026.
Qsemble Capital Management sold 4,937 BridgeBio Pharma shares in Q2 2026, an estimated $346K.
BridgeBio Pharma made up 0.3% of Qsemble Capital Management's portfolio in Q2 2026, its #127 holding.
Qsemble Capital Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 5 quarters since.
Qsemble Capital Management's BridgeBio Pharma position peaked at $2.87M in Q3 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.